RARβ, CDKN2A, DAPK, RASSF1A and MGMT were examined, and the analysis showed that a patient having methylation of just one gene had an odds ratio of 5.08, meaning they were approximately five times likely to have lung cancer than patients without any methylated genes. This evidence concerns the gene CDKN2A and lung carcinoma.